Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial

Table 4 Change in FACT-F score

	QW	EDS	Difference
	(n = 374)	(n = 378)	(QW - EDS)
Baseline FACT-F score
Patients included in the analysis^a	330	337
Mean (SD)	29.7 (12.4)	29.9 (12.4)
Change in FACT-F score from baseline to Week 13
Patients included in the analysis^b	256	268
Least squares mean (95% CI) ^c	1.8 (0.5, 3.1)	2.5 (1.2, 3.7)	-0.7 (-2.3, 0.9)
≥3-point increase in FACT-F score from baseline
Patients included in the analysis^a	330	337
Through Week 13, n (%)	111 (34)	132 (39)
Through the end of treatment, n (%)	155 (47)	173 (51)

^aPatients missing a valid baseline and post-baseline FACT-F score were omitted from the analysis
^bPatients missing a valid baseline and Week 13 FACT-F score were omitted from the analysis
^cThe least squares means and CIs were computed from an ANOVA model after adjusting for the stratification factors at randomization (chemotherapy cycle length, screening hemoglobin, and tumor type), and baseline FACT-F score.
FACT-F = Functional Assessment of Cancer Therapy-Fatigue; QW = once weekly; EDS = extended dosing schedule; SD = standard deviation; CI = confidence interval; ANOVA = analysis of variance

ISSN: 1471-2407